Life Science News

Company News

M Pharmaceutical Inc. (CSE:MQ,OTCQB:MPHMF) announced that highly-touted University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe, MD, MSc, FRCS(C), FACS, will be joining the Advisory Board effective immediately.

M Pharmaceutical Inc. (CSE:MQ,OTCQB:MPHMF) announced that highly-touted University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe, MD, MSc, FRCS(C), FACS, will be joining the Advisory Board effective immediately. Dr. Bathe has served as the provincial leader of the Gastrointestinal Tumour Team at the Tom Baker Centre for the past two years. With residencies and clinical fellowships at institutions as varied as St. Paul’s Hospital in Vancouver, the University of Miami’s Sylvester Comprehensive Cancer Care Centre and University of British Columbia, Dr. Bathe brings with him an international track record in diabetes research, surgery and oncology.
As quoted in the press release:

Dr. Bathe, a graduate of Simon Fraser University, the University of Calgary and the University of British Columbia who currently serves at the Division of Surgical Oncology at the Tom Baker Cancer Centre and is a member of the Julia McFarlane Diabetes Center at the University of Calgary, brings to M Pharmaceutical, Inc. an impressive background in a number of specializations, including metabolomics, cancer surgery, epidemiology, and critical care.
Named a full Professor in the Departments of Surgery and Oncology at the University of Calgary in April of 2012, Dr. Bathe has served as the provincial leader of the Gastrointestinal Tumour Team at the Tom Baker Centre for the past two years.
“The wealth and scope of knowledge associated with Dr. Bathe, especially in areas of diabetes, gastrointestinal and hepatobiliary surgery, and critical care, will only strengthen our company’s capacity in the pursuit of excellence with respect to our innovative biomedical technologies,” said Dr. Martin Mintchev, President & Chief Executive Officer of M Pharmaceutical, Inc. “Given his expertise in areas of specialization such as gastrointestinal surgery, and diabetes mellitus, he is a natural fit for our company as we move toward the final development and launch of M Pharmaceutical biomedical technologies such as the e-Mosquito, gastro-intestinal neurostimulators and pseudobezoars.”
With residencies and clinical fellowships at institutions as varied as St. Paul’s Hospital in Vancouver, the University of Miami’s Sylvester Comprehensive Cancer Care Centre and University of British Columbia, Dr. Bathe brings with him an international track record in diabetes research, surgery and oncology.
His career has been built not only on the strength of numerous professional awards and scholarships in his fields of expertise, but also on his reputation for teaching and mentorship. His students have gone on to win more than 30 individual awards and scholarships in Canada and throughout North America. Dr. Bathe is also widely-published in his core fields of diabetes mellitus, surgery and oncology.

M Pharmaceutical CEO, Dr. Mintchev, said:

We welcome Dr. Bathe to an M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Douglas Janzen, Dr. Orly Yadid-Pecht and Dr. Michel Fattouche. Their guidance and leadership will add value to our strategic plan around product development and commitment to providing positive solutions for those living with obesity and diabetes.

Click here for the full M Pharmaceutical Inc (CSE:MQ,OTCQB:MPHMF) press release.
Click here for the M Pharmaceutical Inc (CSE:MQ,OTCQB:MPHMF) profile. 

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1834.80+3.79
Silver21.35+0.21
Copper3.79+0.05
Palladium1894.40+17.40
Platinum916.50+5.50
Oil107.65+0.03
Heating Oil4.250.00
Natural Gas6.15-0.07

DOWNLOAD FREE REPORTS

×